548 related articles for article (PubMed ID: 20826737)
1. Improved endpoints for cancer immunotherapy trials.
Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
[TBL] [Abstract][Full Text] [Related]
2. Evolution of end points for cancer immunotherapy trials.
Hoos A
Ann Oncol; 2012 Sep; 23 Suppl 8():viii47-52. PubMed ID: 22918928
[TBL] [Abstract][Full Text] [Related]
3. The hazards of endpoints.
Berry DA
J Natl Cancer Inst; 2010 Sep; 102(18):1376-7. PubMed ID: 20826734
[No Abstract] [Full Text] [Related]
4. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
Bilusic M; Gulley JL
Cancer Immunol Immunother; 2012 Jan; 61(1):109-17. PubMed ID: 22120693
[TBL] [Abstract][Full Text] [Related]
5. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Wolchok JD; Hoos A; O'Day S; Weber JS; Hamid O; Lebbé C; Maio M; Binder M; Bohnsack O; Nichol G; Humphrey R; Hodi FS
Clin Cancer Res; 2009 Dec; 15(23):7412-20. PubMed ID: 19934295
[TBL] [Abstract][Full Text] [Related]
7. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
8. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
Shore ND
Immunotherapy; 2014; 6(3):235-47. PubMed ID: 24762070
[TBL] [Abstract][Full Text] [Related]
9. Some statistical considerations in the clinical development of cancer immunotherapies.
Huang B
Pharm Stat; 2018 Feb; 17(1):49-60. PubMed ID: 29098766
[TBL] [Abstract][Full Text] [Related]
10. Exploration of a Novel Intermediate Response Endpoint in Immunotherapy Clinical Studies.
Gao X; Zhang L; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2262-2267. PubMed ID: 29279318
[No Abstract] [Full Text] [Related]
11. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen TT
BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
[TBL] [Abstract][Full Text] [Related]
12. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Anagnostou V; Yarchoan M; Hansen AR; Wang H; Verde F; Sharon E; Collyar D; Chow LQM; Forde PM
Clin Cancer Res; 2017 Sep; 23(17):4959-4969. PubMed ID: 28864724
[TBL] [Abstract][Full Text] [Related]
13. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.
Chen TT
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26113579
[TBL] [Abstract][Full Text] [Related]
14. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
15. Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
Mick R; Chen TT
Cancer Immunol Res; 2015 Dec; 3(12):1292-8. PubMed ID: 26644449
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
18. [New directions in immunotherapy for malignant solid tumors].
Okuno K; Sugiura F; Sukegawa Y; Inoue K
Nihon Rinsho; 2012 Dec; 70(12):2075-86. PubMed ID: 23259377
[TBL] [Abstract][Full Text] [Related]
19. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]